$2.6 Million Seed Funding Propels Amplified Sciences Toward a Future of Transformative Diagnostics

West Lafayette, Ind. (November 25, 2024) –Amplified Sciences, a rising leader in diagnostics technology, today announces the completion of a $2.6 million Series Seed Preferred round. This latest investment round was co-led by Elevate Ventures and OCA Ventures with additional backing from Purdue Strategic Ventures, IU Ventures, Vision Tech, and Flywheel Fund.  

This investment shows continued confidence and belief in Amplified Sciences’ mission to deliver innovative diagnostic solutions that enable earlier detection, precise risk assessment, and ongoing monitoring of serious diseases.

“This funding allows us to make significant strides toward our vision of a world transformed by earlier and more precise disease detection. BioMatraTM, our ultra-sensitive molecular sensing platform, combines advanced chemistry reagents, cutting-edge instrumentation, and AI to deliver extremely accurate results. We are initially applying this breakthrough technology to patients at higher risk for pancreatic cancer,” explains Diana Caldwell, Amplifed’s CEO and cofounder. 

The new capital will be directed toward furthering the company’s proprietary platform, expanding its research and development efforts, securing regulatory clearance for the lead assay PanCystProTM, and initiating a clinical trial to demonstrate the test’s clinical utility. 

The company is focused on developing actionable diagnostics of cancer and other serious diseases to enable earlier detection, better treatment and ultimately better outcomes for the patient.  

“Our investment in Amplified Sciences is a testament to their innovative approach to multi-dimensional biomarker detection and their powerhouse team who have brought forward a portfolio of diagnostic tests,” shares Toph Day, CEO of Elevate Ventures. 

To learn more about Amplified Sciences, visit amplifiedsciences.com.